Canada markets open in 4 hours 59 minutes

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
41.16-0.04 (-0.10%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close41.20
BidN/A x N/A
AskN/A x N/A
Day's Range40.89 - 41.32
52 Week Range37.88 - 53.86
Avg. Volume2,140,485
Market Cap274.107B
Beta (5Y Monthly)0.29
PE Ratio (TTM)17.90
EPS (TTM)2.30
Earnings DateN/A
Forward Dividend & Yield1.24 (3.01%)
Ex-Dividend DateMar 17, 2022
1y Target Est46.25
  • Zacks

    Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust

    Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.

  • Zacks

    Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark

    Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.

  • Business Wire

    Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results

    SOUTH SAN FRANCISCO, Calif., August 02, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq® (atezolizumab) met its co-primary endpoints. The study showed non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with intravenous (IV) infusion, in cancer immunotherapy-naïve patients with locally advanced or metastatic non-smal